Brooke E. Howitt

Jan 8, 2025 | nature.com | Robert R. Stickels |Zaki Abou-Mrad |Viviane Tabar |Brooke E. Howitt |Leif S. Ludwig |Ronan Chaligné | +1 more

AbstractSingle-cell genomics technologies have accelerated our understanding of cell-state heterogeneity in diverse contexts. Although single-cell RNA sequencing identifies rare populations that express specific marker transcript combinations, traditional flow sorting requires cell surface markers with high-fidelity antibodies, limiting our ability to interrogate these populations.

Nov 6, 2024 | nature.com | Oriol Pich |Kerstin Thol |Jens Luebeck |Natasha E. Weiser |Wei-Ting Lu |Brooke E. Howitt | +11 more

AbstractExtrachromosomal DNA (ecDNA) is a major contributor to treatment resistance and poor outcome for patients with cancer1,2. Here we examine the diversity of ecDNA elements across cancer, revealing the associated tissue, genetic and mutational contexts. By analysing data from 14,778 patients with 39 tumour types from the 100,000 Genomes Project, we demonstrate that 17.1% of tumour samples contain ecDNA.

Aug 23, 2024 | nature.com | Christine Yeh |Olivia Laveroni |Subin Kim |Aihui Wang |Brooke Liang |Raeline Valbuena | +4 more

AbstractThe drivers of immune evasion are not entirely clear, limiting the success of cancer immunotherapies. Here we applied single-cell spatial and perturbational transcriptomics to delineate immune evasion in high-grade serous tubo-ovarian cancer. To this end, we first mapped the spatial organization of high-grade serous tubo-ovarian cancer by profiling more than 2.5 million cells in situ in 130 tumors from 94 patients.

Jun 18, 2024 | onlinelibrary.wiley.com | Lynn Hoang |Brooke E. Howitt |Teri A. Longacre |Mona Alafraidi

Introduction Decreased oestrogen receptor (ER) expression is a robust prognostic biomarker in endometrial carcinoma.